Developer docs
API playgroundTry for free, no card

Search company profiles

Prolight Diagnostics

Full company profile

uuid0003t9u

Namestring
Prolight Diagnostics
Legal namestring
Prolight Diagnostics AB
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Prolight Diagnostics AB is a privately held Swedish medical diagnostics company founded in 1999 and headquartered in Lund, Sweden. The company develops patient-near analysis (PNA) / point-of-care (POC) diagnostic systems intended to deliver laboratory-quality results outside traditional hospital laboratories. Its target end users are emergency departments, ambulances, healthcare centers, and nursing homes that require rapid diagnostic results for time-critical conditions, with the initial commercial focus on acute heart attack detection via high-sensitivity troponin measurement.

The company's core product is the Psyros® platform, a digital POC instrument built on proprietary single molecule counting technology. The method uses thresholding to determine whether the signal from each molecule is on or off, eliminating background noise and enabling measurement of ultra-low biomarker concentrations from a single drop of blood, with results delivered in 10 minutes or less. The platform supports multiplex testing for multiple biomarkers simultaneously and is being designed for reliable operation in demanding clinical environments such as ambulances and emergency departments. A secondary product, MicroFlex, extends the POC portfolio with disposable test cards for in-vitro diagnostic testing. Psyros® achieved formal design freeze in April 2026 with manufacturing partner G&H | ITL and is progressing into pilot unit production.

Prolight operates in a pre-commercial stage and has not disclosed revenue. The planned business model centers on direct enterprise sales of small mobile diagnostic instruments with recurring single-use test cards to hospitals, emergency services, and NHS-type healthcare facilities. Key collaborations include a UK clinical and manufacturing consortium (Guy's and St Thomas' NHS Foundation Trust, King's College London, Lightning Health, and G&H | ITL) supported by a SEK 17 million (£1.26 million) NIHR i4i Product Development Award, plus a 2026 collaboration with BRAINBox Solutions extending the platform into traumatic brain injury and neurodegenerative disease diagnostics.

Short descriptiontext

Prolight Diagnostics AB is a Swedish pre-commercial medical diagnostics company developing the Psyros® digital point-of-care platform, which uses proprietary single molecule counting to deliver ultra-sensitive biomarker results from a drop of blood in under 10 minutes for emergency and acute care settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, in-vitro diagnostics, cardiac biomarker testing, single molecule counting, patient-near analysis
Industry3 codes
PRIMARYHLAHAOAC
Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Point-of-Care Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Point-of-Care Diagnostic Instruments and Test Cards
TypeHardware Sales
Description

Prolight Diagnostics generates revenue through the sale of small mobile diagnostic instruments with single-use test cards for point-of-care testing. Healthcare providers purchase instruments and ongoing test cards for patient testing in ambulances, emergency departments, healthcare centers, and nursing homes.

prolightdx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Psyros
Description

Digital point-of-care diagnostic platform using single molecule counting technology for rapid detection of acute health events including heart attack detection.

prolightdx.com
+2 more records
Core offering1 text field

Prolight Diagnostics AB develops small mobile point-of-care (POC) / patient-near analysis (PNA) diagnostic instruments with single-use test cards that perform in-vitro diagnostic (IVD) tests from a drop of blood outside traditional hospital laboratories. The flagship Psyros® platform uses proprietary digital single molecule counting technology to deliver reliable results in 10 minutes or less, enabling ultra-sensitive biomarker detection such as high-sensitivity troponin for acute cardiac events. The MicroFlex system complements the portfolio with disposable test cards for IVD testing in ambulances, emergency departments, healthcare centers, and nursing homes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10 minutes or less for reliable diagnostic results at point of care
+2 more records
Product overview1 text field

Prolight Diagnostics AB develops a portfolio of point-of-care (POC) diagnostic systems consisting of the Psyros® platform and MicroFlex product line. Psyros® is a digital POC platform that utilizes proprietary single molecule counting technology, representing a paradigm shift from traditional analog POC systems. MicroFlex provides additional POC testing capability. Both products are small mobile instruments with single-use test cards that perform IVD tests from a blood drop, designed for use in ambulances, emergency departments, healthcare centers, and nursing homes.

Product and service1 record
1Psyros®
CategoryPoint-of-Care Diagnostic Instrument
Description

Digital point-of-care diagnostic platform using proprietary single molecule counting technology to deliver reliable test results in 10 minutes or less from a single drop of blood, with multiplex biomarker capability. Designed for ultra-sensitive detection of biomarkers such as high-sensitivity troponin for acute heart attack detection in ambulances, emergency departments, healthcare centers, and nursing homes.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1G&H | ITL
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

Development and manufacturing partner for the Psyros point-of-care diagnostic instrument. G&H collaborated on achieving formal design freeze with improvements in mechanical and optical stability to support scalable manufacturing and reliable operation in demanding clinical environments. Now proceeding with pilot unit production for system verification and validation.

tradingview.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Collaboration announced for point-of-care testing, aiming to create precision diagnostic tools for traumatic brain injury (TBI) and neurodegenerative diseases, combining Prolight's Psyros technology with BRAINBox's diagnostic programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Collaboration with Prolight Diagnostics on the NIHR i4i Product Development Award for Psyros platform development. The NHS Foundation Trust provides clinical expertise and hosts pre-validation studies at St Thomas' Hospital before clinical validation in 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Academic partner in the NIHR i4i funded collaboration contributing research expertise and academic rigor to the Psyros platform development alongside NHS and industry partners.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Industry partner in the NIHR i4i Product Development Award collaboration supporting product development, pilot manufacturing, clinical studies, and technical submissions for the Psyros platform.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

QuidelOrtho is a large diagnostics company offering the Triage family of point-of-care cardiovascular tests including high-sensitivity troponin assays. It is a broad incumbent competing with Prolight's Psyros in the cardiac POC market and serves similar emergency and acute care customers.

2Abbott
TypeBroad incumbent
Description

Abbott offers the i-STAT system, one of the most widely deployed point-of-care platforms globally, with troponin and other cardiac assays used in EDs and ambulances. It is a broad incumbent in cardiac POC testing and a direct competitor to Prolight's Psyros platform.

TypeBroad incumbent
Description

Roche offers the cobas h232 POC system and central lab troponin assays used in cardiac diagnostics. It is a broad incumbent with both POC and central laboratory offerings overlapping Prolight's intended use cases in acute care.

TypeBroad incumbent
Description

Siemens Healthineers offers the Atellica VTLI patient-side blood analyzer and broader cardiac diagnostics portfolio. As a broad incumbent in clinical diagnostics and POC testing, it competes with Prolight in the acute care and ED segments targeted by Psyros.

TypeDirect peer
Description

Response Biomedical develops rapid point-of-care cardiovascular tests including troponin assays on its RAMP platform. It is a direct peer to Prolight given its focus on rapid cardiac biomarker POC testing in emergency and acute care settings.

6Boditech Med
TypeEmerging player
Description

Boditech Med manufactures point-of-care immunoassay analyzers and cardiac biomarker tests including troponin, primarily serving Asian and emerging markets. It is an emerging player with overlapping cardiac POC capabilities to Prolight's Psyros.

TypeDirect peer
Description

Mesa Labs offers the QC product line and has historically been involved in rapid cardiac diagnostics including troponin POC testing through its acquisition of several diagnostic platforms. It is a direct peer in cardiac point-of-care diagnostics serving similar customer workflows.

TypeBroad incumbent
Description

Philips developed the Minicare POC platform aimed at acute care diagnostics including cardiac biomarkers. As a broad incumbent with established hospital relationships and patient monitoring offerings, it is comparable to Prolight's broader POC ambitions beyond just cardiac.

TypeEmerging player
Description

Poclight develops single-use POC diagnostic devices with focus on rapid biomarker testing. It is an emerging player with overlapping POC technology ambitions and similar target customers to Prolight in acute and emergency settings.

TypeBroad incumbent
Description

BioMérieux is a global in vitro diagnostics company offering a broad portfolio including immunoassay platforms used for cardiac and critical care diagnostics. It is a broad incumbent in clinical diagnostics with adjacent technology and customer overlap with Prolight's POC ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prolight Diagnostics

Point-of-Care Diagnosticsprolightdiagnostics.se

Prolight Diagnostics AB is a Swedish pre-commercial medical diagnostics company developing the Psyros® digital point-of-care platform, which uses proprietary single molecule counting to deliver ultra-sensitive biomarker results from a drop of blood in under 10 minutes for emergency and acute care settings.

What Prolight Diagnostics does

Prolight Diagnostics AB is a privately held Swedish medical diagnostics company founded in 1999 and headquartered in Lund, Sweden. The company develops patient-near analysis (PNA) / point-of-care (POC) diagnostic systems intended to deliver laboratory-quality results outside traditional hospital laboratories. Its target end users are emergency departments, ambulances, healthcare centers, and nursing homes that require rapid diagnostic results for time-critical conditions, with the initial commercial focus on acute heart attack detection via high-sensitivity troponin measurement.

The company's core product is the Psyros® platform, a digital POC instrument built on proprietary single molecule counting technology. The method uses thresholding to determine whether the signal from each molecule is on or off, eliminating background noise and enabling measurement of ultra-low biomarker concentrations from a single drop of blood, with results delivered in 10 minutes or less. The platform supports multiplex testing for multiple biomarkers simultaneously and is being designed for reliable operation in demanding clinical environments such as ambulances and emergency departments. A secondary product, MicroFlex, extends the POC portfolio with disposable test cards for in-vitro diagnostic testing. Psyros® achieved formal design freeze in April 2026 with manufacturing partner G&H | ITL and is progressing into pilot unit production.

Prolight operates in a pre-commercial stage and has not disclosed revenue. The planned business model centers on direct enterprise sales of small mobile diagnostic instruments with recurring single-use test cards to hospitals, emergency services, and NHS-type healthcare facilities. Key collaborations include a UK clinical and manufacturing consortium (Guy's and St Thomas' NHS Foundation Trust, King's College London, Lightning Health, and G&H | ITL) supported by a SEK 17 million (£1.26 million) NIHR i4i Product Development Award, plus a 2026 collaboration with BRAINBox Solutions extending the platform into traumatic brain injury and neurodegenerative disease diagnostics.

Prolight Diagnostics firmographics

Firmographics
Name
Prolight Diagnostics
Legal name
Prolight Diagnostics AB
Website
https://prolightdiagnostics.se
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Prolight Diagnostics AB is a Swedish pre-commercial medical diagnostics company developing the Psyros® digital point-of-care platform, which uses proprietary single molecule counting to deliver ultra-sensitive biomarker results from a drop of blood in under 10 minutes for emergency and acute care settings.
Ownership category
akta.pro rank

Prolight Diagnostics industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAC
Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Point-of-care diagnostics
  • In-vitro diagnostics
  • Cardiac biomarker testing
  • Single molecule counting
  • Patient-near analysis

Where Prolight Diagnostics is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Prolight Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Point-of-Care Diagnostic Instruments and Test Cards: Prolight Diagnostics generates revenue through the sale of small mobile diagnostic instruments with single-use test cards for point-of-care testing. Healthcare providers purchase instruments and ongoing test cards for patient testing in ambulances, emergency departments, healthcare centers, and nursing homes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Prolight Diagnostics product offering

Product offering

Core offering

Prolight Diagnostics AB develops small mobile point-of-care (POC) / patient-near analysis (PNA) diagnostic instruments with single-use test cards that perform in-vitro diagnostic (IVD) tests from a drop of blood outside traditional hospital laboratories. The flagship Psyros® platform uses proprietary digital single molecule counting technology to deliver reliable results in 10 minutes or less, enabling ultra-sensitive biomarker detection such as high-sensitivity troponin for acute cardiac events. The MicroFlex system complements the portfolio with disposable test cards for IVD testing in ambulances, emergency departments, healthcare centers, and nursing homes.

Product overview

Prolight Diagnostics AB develops a portfolio of point-of-care (POC) diagnostic systems consisting of the Psyros® platform and MicroFlex product line. Psyros® is a digital POC platform that utilizes proprietary single molecule counting technology, representing a paradigm shift from traditional analog POC systems. MicroFlex provides additional POC testing capability. Both products are small mobile instruments with single-use test cards that perform IVD tests from a blood drop, designed for use in ambulances, emergency departments, healthcare centers, and nursing homes.

Differentiator

Problem solved

Functional benefit

Brands

  • Psyros: Digital point-of-care diagnostic platform using single molecule counting technology for rapid detection of acute health events including heart attack detection.
  • Psyros®
  • MicroFlex

Products and services

  • Psyros® Digital point-of-care diagnostic platform using proprietary single molecule counting technology to deliver reliable test results in 10 minutes or less from a single drop of blood, with multiplex biomarker capability. Designed for ultra-sensitive detection of biomarkers such as high-sensitivity troponin for acute heart attack detection in ambulances, emergency departments, healthcare centers, and nursing homes.

Quantifiable outcome

  • 10 minutes or less for reliable diagnostic results at point of care
  • +2 more outcomes

Companies that use Prolight Diagnostics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Prolight Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Prolight Diagnostics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • G&H | ITLcoreTechnology or Integration · 1 April 2026Development and manufacturing partner for the Psyros point-of-care diagnostic instrument. G&H collaborated on achieving formal design freeze with improvements in mechanical and optical stability to support scalable manufacturing and reliable operation in demanding clinical environments. Now proceeding with pilot unit production for system verification and validation.
  • BRAINBox SolutionsminorStrategic or Co-development Partner · 1 March 2026Collaboration announced for point-of-care testing, aiming to create precision diagnostic tools for traumatic brain injury (TBI) and neurodegenerative diseases, combining Prolight's Psyros technology with BRAINBox's diagnostic programs.
  • Guy's and St Thomas' NHS Foundation TrustcoreStrategic or Co-development Partner · 1 May 2024Collaboration with Prolight Diagnostics on the NIHR i4i Product Development Award for Psyros platform development. The NHS Foundation Trust provides clinical expertise and hosts pre-validation studies at St Thomas' Hospital before clinical validation in 2025.
  • King's College LondoncoreStrategic or Co-development Partner · 1 May 2024Academic partner in the NIHR i4i funded collaboration contributing research expertise and academic rigor to the Psyros platform development alongside NHS and industry partners.
  • Lightning HealthcoreStrategic or Co-development Partner · 1 May 2024Industry partner in the NIHR i4i Product Development Award collaboration supporting product development, pilot manufacturing, clinical studies, and technical submissions for the Psyros platform.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Prolight Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • QuidelOrtho: QuidelOrtho is a large diagnostics company offering the Triage family of point-of-care cardiovascular tests including high-sensitivity troponin assays. It is a broad incumbent competing with Prolight's Psyros in the cardiac POC market and serves similar emergency and acute care customers.
  • Abbott: Abbott offers the i-STAT system, one of the most widely deployed point-of-care platforms globally, with troponin and other cardiac assays used in EDs and ambulances. It is a broad incumbent in cardiac POC testing and a direct competitor to Prolight's Psyros platform.
  • Roche Diagnostics: Roche offers the cobas h232 POC system and central lab troponin assays used in cardiac diagnostics. It is a broad incumbent with both POC and central laboratory offerings overlapping Prolight's intended use cases in acute care.
  • Siemens Healthineers: Siemens Healthineers offers the Atellica VTLI patient-side blood analyzer and broader cardiac diagnostics portfolio. As a broad incumbent in clinical diagnostics and POC testing, it competes with Prolight in the acute care and ED segments targeted by Psyros.
  • Philips (BioTelemetry / Minicare): Philips developed the Minicare POC platform aimed at acute care diagnostics including cardiac biomarkers. As a broad incumbent with established hospital relationships and patient monitoring offerings, it is comparable to Prolight's broader POC ambitions beyond just cardiac.
  • BioMérieux: BioMérieux is a global in vitro diagnostics company offering a broad portfolio including immunoassay platforms used for cardiac and critical care diagnostics. It is a broad incumbent in clinical diagnostics with adjacent technology and customer overlap with Prolight's POC ambitions.

Direct peers

  • Response Biomedical: Response Biomedical develops rapid point-of-care cardiovascular tests including troponin assays on its RAMP platform. It is a direct peer to Prolight given its focus on rapid cardiac biomarker POC testing in emergency and acute care settings.
  • Mesa Labs: Mesa Labs offers the QC product line and has historically been involved in rapid cardiac diagnostics including troponin POC testing through its acquisition of several diagnostic platforms. It is a direct peer in cardiac point-of-care diagnostics serving similar customer workflows.

Emerging players

  • Boditech Med: Boditech Med manufactures point-of-care immunoassay analyzers and cardiac biomarker tests including troponin, primarily serving Asian and emerging markets. It is an emerging player with overlapping cardiac POC capabilities to Prolight's Psyros.
  • ET Healthcare (Poclight): Poclight develops single-use POC diagnostic devices with focus on rapid biomarker testing. It is an emerging player with overlapping POC technology ambitions and similar target customers to Prolight in acute and emergency settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Prolight Diagnostics social profiles

Digital presence

Prolight Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prolight Diagnostics leadership team

Management profile

Number of profiles

Prolight Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prolight Diagnostics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prolight Diagnostics

What does Prolight Diagnostics do?

Prolight Diagnostics AB develops small mobile point-of-care (POC) / patient-near analysis (PNA) diagnostic instruments with single-use test cards that perform in-vitro diagnostic (IVD) tests from a drop of blood outside traditional hospital laboratories. The flagship Psyros® platform uses proprietary digital single molecule counting technology to deliver reliable results in 10 minutes or less, enabling ultra-sensitive biomarker detection such as high-sensitivity troponin for acute cardiac events. The MicroFlex system complements the portfolio with disposable test cards for IVD testing in ambulances, emergency departments, healthcare centers, and nursing homes.

Is Prolight Diagnostics a public or private company?

Prolight Diagnostics is a private company. It is classified as unknown and is currently operating.

When was Prolight Diagnostics founded?

Prolight Diagnostics was founded in 1999. It employs 11 to 50 people.

Where is Prolight Diagnostics based?

Prolight Diagnostics is headquartered in Lund, Sweden, in the Europe region.

How does Prolight Diagnostics make money?

One revenue line is on record: point-of-Care Diagnostic Instruments and Test Cards.

Who are Prolight Diagnostics's main competitors?

Broad incumbents on record are QuidelOrtho, Abbott, Roche Diagnostics, Siemens Healthineers, Philips (BioTelemetry / Minicare) and BioMérieux. Direct peers are Response Biomedical and Mesa Labs. Emerging players are Boditech Med and ET Healthcare (Poclight).

Does Prolight Diagnostics have an API?

No public API is recorded for Prolight Diagnostics.

What industry is Prolight Diagnostics in?

Prolight Diagnostics's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAOAC, Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkBRAINBox and Prolight sign supply agreement for concussion testsBRAINBox Solutions signed an agreement with Prolight Diagnostics to supply Psyros instruments and cartridges for its concussion diagnostic tests. The deal follows a feasibility study using 260 patient samples from BRAINBox's HeadSMART II trial, which showed strong performance. The companies aim to commercialize the tests for point-of-care settings.PR NewswireBRAINBox Solutions Announces Agreement with Prolight Diagnostics for Commercial Supply of Pyros® Devices for Delivery of BRAINBox Concussion Diagnostics/Prognostics at Point-of-CareBRAINBox Solutions announced an agreement with Prolight Diagnostics to supply Pyros instruments and cartridges for point-of-care delivery of its concussion diagnostic tests. The collaboration followed a feasibility study evaluating 260 patient samples, and the company plans to prepare for market launch of its TBI tests.PR NewswireBRAINBox Solutions Announces Strategic Financing to Advance Development of Point-of-Care Concussion Diagnostic/PrognosticsBRAINBox Solutions announced strategic financing from Pivotal Capital Partners and New Horizon Bank to advance point-of-care and lab-based devices for its concussion diagnostic tests. The funding will support development of advanced hardware and software and acquisition of pilot instruments, following a successful feasibility study with Prolight Diagnostics.NewswiseFrom Concept to Commercialization: G&H to Demonstrate End-to-End Diagnostic Instrument Development at ADLM 2026G&H (LON: GHH) announced it will showcase its end-to-end diagnostic instrument development and manufacturing capabilities at the ADLM Clinical Lab Expo 2026 in Anaheim, California, from July 28–30. The company, through its integrated business G&H | ITL, will highlight its multidisciplinary engineering, precision optics, photonics, and ISO 13485-certified manufacturing services designed to help diagnostic and medical device companies accelerate product development and commercialization. Featured customer collaborations include the Psyros™ point-of-care diagnostic platform, developed with Prolight Diagnostics, which was selected as a semi-finalist in the ADLM 2026 Disruptive Technology Award Competition.News-MedicalG&H highlights end-to-end diagnostic device development at ADLM 2026G&H will showcase its diagnostic device development services at ADLM 2026, including the Psyros point-of-care platform with Prolight Diagnostics. The company offers engineering, photonics, and ISO 13485-certified manufacturing to accelerate product commercialization. It also highlights past projects like Magnasense and OrganOx.MarketScreenerProlight Diagnostics Signs Development Deal with BrainBox SolutionsProlight Diagnostics AB has signed a development deal with BrainBox Solutions. Prolight Diagnostics is a Sweden-based medical technology company that develops patient-close test systems for Point of Care Testing, focusing on the heart marker troponin.Dagens industriProlight tar avtal värt 29 miljonerProlight Diagnostics has signed a development agreement with Brainbox Solutions that will generate revenues of approximately 29 million Swedish kronor. The agreement represents a notable contract win for Prolight Diagnostics in its ongoing development activities. Published on July 13, 2026.TradingViewProlight Diagnostics achieves design freeze for Psyros® instrumentProlight Diagnostics announced the achievement of formal design freeze for its Psyros point-of-care diagnostic instrument, a milestone completed in collaboration with development and manufacturing partner G&H | ITL. The finalized design incorporates improvements in mechanical and optical stability to support scalable manufacturing and reliable operation in demanding clinical environments such as ambulances and emergency departments. The company will now proceed with pilot unit production for system verification and validation, followed by regulatory clinical performance studies.Clinical Lab ProductsConcussion Blood Test Advances Toward FDA Submission With Point-of-Care CollaborationBRAINBox Solutions announced near-completion of its HeadSMART II pivotal clinical trial, which is evaluating over 2,000 samples to support an FDA marketing clearance submission for its concussion diagnostic test in adults. The company also reported promising early results from a point-of-care collaboration with Prolight Diagnostics to incorporate its biomarkers into the Psyros single-molecule platform, advancing to a validation phase using 260-patient samples from the trial. Additionally, BRAINBox presented machine learning models designed to differentiate TBI from dementia in elderly patients at two scientific conferences, with the National Institutes of Health funding the geriatric patient population clinical trial.optics.orgG&H to Demonstrate Integrated Photonics Platforms for Scaled Deployment at SPIE Photonics West and BiOS Expo 2026G&H (LON: GHH), a UK-based photonics and optical systems manufacturer, will exhibit at SPIE Photonics West and BiOS Expo 2026 in San Francisco from January 17–22, 2026, to demonstrate its vertically integrated photonics platforms across aerospace, defense, industrial, telecom, and life sciences markets. The company will showcase OEM photonic modules supporting OCT applications in ophthalmology, cardiology, and skin cancer screening, along with the Psyros point-of-care blood analysis technology developed in partnership with Prolight Diagnostics for rapid detection of acute health events. G&H's Optical Systems division, strengthened by recent acquisitions including Global Photonics (now operating as G&H Tampa), will also highlight its advanced optical solutions for avionics and mission-critical defense environments.